Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction

Recent evidence suggests that loss of endothelial barrier function and resulting microvascular leak play important mechanistic roles in the pathogenesis of infection-related end-organ dysfunction and failure. Several distinct therapeutic strategies, designed to prevent or limit infection-related microvascular endothelial activation and permeability, thereby mitigating end-organ injury/dysfunction, have recently been investigated in pre-clinical models. In this review, these potential therapeutic strategies, namely, VEGFR2/Src antagonists, sphingosine-1-phosphate agonists, fibrinopeptide Bβ15–42, slit2N, secinH3, angiopoietin-1/tie-2 agonists, angiopoietin-2 antagonists, statins, atrial natriuretic peptide, and mesenchymal stromal (stem) cells, are discussed in terms of their translational potential for the management of clinical infectious diseases.

[1]  Jae W. Lee,et al.  Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1 , 2007, The Journal of Immunology.

[2]  A. Ridley,et al.  Rho and Rac but not Cdc42 regulate endothelial cell permeability. , 2001, Journal of cell science.

[3]  P. Rollin,et al.  Andes Virus Disrupts the Endothelial Cell Barrier by Induction of Vascular Endothelial Growth Factor and Downregulation of VE-Cadherin , 2010, Journal of Virology.

[4]  C. Esmon,et al.  Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury , 2008, Thorax.

[5]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[6]  C. Peters,et al.  Role of the endothelium in viral hemorrhagic fevers , 2002, Critical care medicine.

[7]  J. Greenwood,et al.  Statins and the vascular endothelial inflammatory response. , 2007, Trends in immunology.

[8]  J. Gutkind,et al.  VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin , 2006, Nature Cell Biology.

[9]  E. Mackow,et al.  Endothelial Cells Elicit Immune-Enhancing Responses to Dengue Virus Infection , 2012, Journal of Virology.

[10]  Brian J. Ell,et al.  Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor , 2009, The Journal of experimental medicine.

[11]  K. Claffey,et al.  Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate , 1999, Cell.

[12]  P. Friedl,et al.  Peptide Bβ15-42 Preserves Endothelial Barrier Function in Shock , 2009, PloS one.

[13]  S. Pyne,et al.  Translational aspects of sphingosine 1-phosphate biology. , 2011, Trends in molecular medicine.

[14]  Dean Y. Li,et al.  Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability , 2012, Nature.

[15]  S. Pyne,et al.  Sphingosine 1-phosphate signalling in mammalian cells. , 2000, The Biochemical journal.

[16]  D. Fliser,et al.  Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome , 2010, Intensive Care Medicine.

[17]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[18]  Robert Peach,et al.  Endothelial Cells Are Central Orchestrators of Cytokine Amplification during Influenza Virus Infection , 2011, Cell.

[19]  G. Yancopoulos,et al.  Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells , 2006, Proceedings of the National Academy of Sciences.

[20]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[21]  R. Sugrue,et al.  Lovastatin treatment mitigates the pro-inflammatory cytokine response in respiratory syncytial virus infected macrophage cells. , 2013, Antiviral research.

[22]  M. Currie,et al.  Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[24]  K. Hirata,et al.  Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. , 2000, Biochemical and biophysical research communications.

[25]  D. Fliser,et al.  Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients , 2008, Critical care.

[26]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[27]  A. Birukova,et al.  ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha. , 2010, Microvascular research.

[28]  Ian Parker,et al.  Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo , 2006, Nature chemical biology.

[29]  Mark D. Williams,et al.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial , 2007, The Lancet.

[30]  Jay Steingrub,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005 .

[31]  Jin Cheng,et al.  Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury , 2008, Critical care medicine.

[32]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[33]  Christopher A. Jones,et al.  Slit2–Robo4 signalling promotes vascular stability by blocking Arf6 activity , 2009, Nature Cell Biology.

[34]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[35]  Jae W. Lee,et al.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2009, Proceedings of the National Academy of Sciences.

[36]  S. Yuan,et al.  Regulation of Endothelial Barrier Function , 2011 .

[37]  K. Kain,et al.  S1P Is Associated with Protection in Human and Experimental Cerebral Malaria , 2011, Molecular medicine.

[38]  D. Stewart,et al.  Cell-based angiopoietin-1 gene therapy for acute lung injury. , 2007, American journal of respiratory and critical care medicine.

[39]  E. Levin,et al.  Deciphering Vascular Endothelial Cell Growth Factor/Vascular Permeability Factor Signaling to Vascular Permeability , 2002, The Journal of Biological Chemistry.

[40]  T. Hla,et al.  Lysophosphatidic Acid Stimulates the G-protein-coupled Receptor EDG-1 as a Low Affinity Agonist* , 1998, The Journal of Biological Chemistry.

[41]  Arthur S Slutsky,et al.  Broken Barriers: A New Take on Sepsis Pathogenesis , 2011, Science Translational Medicine.

[42]  A. Rapraeger,et al.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation , 2010, Journal of Cell Science.

[43]  N. Shapiro,et al.  Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis* , 2012, Critical care medicine.

[44]  A. Bindels,et al.  Atrial natriuretic peptide infusion and nitric oxide inhalation in patients with acute respiratory distress syndrome , 2001, Critical care.

[45]  S. Blankenberg,et al.  Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. , 2002, The American journal of cardiology.

[46]  J. Kimpen,et al.  PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR IN SEVERE SEPSIS , 2005, Shock.

[47]  O. Pachinger,et al.  HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[48]  R. Ganju,et al.  N-terminal Slit2 inhibits HIV-1 replication by regulating the actin cytoskeleton , 2013, Retrovirology.

[49]  Dean Y. Li,et al.  Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza , 2010, Science Translational Medicine.

[50]  Jae W. Lee,et al.  Allogeneic Human Mesenchymal Stem Cells Restore Epithelial Protein Permeability in Cultured Human Alveolar Type II Cells by Secretion of Angiopoietin-1*♦ , 2010, The Journal of Biological Chemistry.

[51]  A. Klibanov,et al.  Atrial natriuretic peptide attenuates LPS-induced lung vascular leak: role of PAK1. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[52]  D. Vestweber,et al.  Control of endothelial barrier function by regulating vascular endothelial-cadherin , 2010, Current opinion in hematology.

[53]  B. Witzenbichler,et al.  Protective Role of Angiopoietin-1 in Endotoxic Shock , 2005, Circulation.

[54]  W. Aird,et al.  Sepsis and the broken endothelium , 2011, Critical care.

[55]  G. Francis,et al.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.

[56]  Naftali Kaminski,et al.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  W. Liles,et al.  Immunomodulatory therapy for severe influenza , 2011, Expert review of anti-infective therapy.

[58]  M. Rojas,et al.  Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[59]  Tami L. Bach,et al.  Endothelial Cell VE-cadherin Functions as a Receptor for the β15–42 Sequence of Fibrin* , 1998, The Journal of Biological Chemistry.

[60]  A. Klibanov,et al.  Atrial natriuretic peptide attenuates LPS-induced lung vascular leak : role of PAK 1 , 2010 .

[61]  H. Augustin,et al.  Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation , 2006, Nature Medicine.

[62]  M. Singer,et al.  Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting? , 2009, Critical care medicine.

[63]  A. Birukova,et al.  Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. , 2011, Journal of applied physiology.

[64]  T. Ohmori,et al.  Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells , 2000 .

[65]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[66]  D. Sheppard,et al.  Absence of integrin αvβ3 enhances vascular leak in mice by inhibiting endothelial cortical actin formation. , 2012, American journal of respiratory and critical care medicine.

[67]  Nigel Mackman,et al.  Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C , 2007, The Journal of experimental medicine.

[68]  K. Claffey,et al.  Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.

[69]  R. Jain,et al.  Leaky vessels? Call Ang1! , 2000, Nature Medicine.

[70]  J. Machan,et al.  Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A. , 2013, Journal of applied physiology.

[71]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[72]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[73]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[74]  P. Dash,et al.  Bone Marrow Derived Mesenchymal Stem Cells Inhibit Inflammation and Preserve Vascular Endothelial Integrity in the Lungs after Hemorrhagic Shock , 2011, PloS one.

[75]  H. Itoh,et al.  Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. , 1994, Biochemical and biophysical research communications.

[76]  C. Feistritzer,et al.  Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. , 2005, Blood.

[77]  J. Pfeilschifter,et al.  SphK1 Regulates Proinflammatory Responses Associated with Endotoxin and Polymicrobial Sepsis , 2010, Science.

[78]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[79]  P. Pickkers,et al.  VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY , 2005, Shock.

[80]  Arthur S Slutsky,et al.  Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. , 2010, American journal of respiratory and critical care medicine.

[81]  P. Zacharowski,et al.  The fibrin-derived peptide Bbeta~1~5~-~4~2 protects the myocardium against ischemia-reperfusion injury , 2005 .

[82]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[83]  C. Orihuela,et al.  Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia , 2012, BMC Microbiology.

[84]  M. Itoh,et al.  Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. , 2003, Microvascular research.

[85]  R. Kammerer,et al.  Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis , 2012, Critical Care.

[86]  J. Gutkind,et al.  Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. , 2008, Developmental cell.

[87]  A. Malik,et al.  Regulation of Endothelial Junctional Permeability , 2008, Annals of the New York Academy of Sciences.

[88]  Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. , 2008, Nature medicine.

[89]  M. Yanagisawa,et al.  Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. , 2005, The Journal of clinical investigation.

[90]  D. Wheeler.  Another potential therapeutic agent for the management of critically ill patients with sepsis syndrome: same old story, same old result?*. , 2012, Critical care medicine.

[91]  E. Mackow,et al.  Hantaviruses Direct Endothelial Cell Permeability by Sensitizing Cells to the Vascular Permeability Factor VEGF, while Angiopoietin 1 and Sphingosine 1-Phosphate Inhibit Hantavirus-Directed Permeability , 2008, Journal of Virology.

[92]  D. Dumont,et al.  Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[93]  Y. Hirata,et al.  Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. , 1998, Chest.

[94]  D. Mukhopadhyay,et al.  Neuropilin-1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor-dependent Endothelial Cell Migration* , 2003, Journal of Biological Chemistry.

[95]  S. Coughlin,et al.  Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. , 2009, The Journal of clinical investigation.

[96]  B. Scheller,et al.  The Fibrinopeptide B&bgr;15-42 Reduces Inflammation in Mice Subjected to Polymicrobial Sepsis , 2012, Shock.

[97]  P. Bianco,et al.  Marrow stromal stem cells. , 2000, The Journal of clinical investigation.

[98]  K. Jang,et al.  COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. , 2009, Kidney international.

[99]  Jae W. Lee,et al.  Potential application of mesenchymal stem cells in acute lung injury , 2009, Expert opinion on biological therapy.

[100]  H. Pavenstädt,et al.  The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis , 2011, Critical care.

[101]  A. Hall,et al.  Rho GTPases and their effector proteins. , 2000, The Biochemical journal.

[102]  Volker Brinkmann,et al.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.

[103]  R. Gamelli,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.

[104]  D. Stewart,et al.  Competing Interests: This work was , 2022 .

[105]  M. Oldstone,et al.  Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm , 2011, Immunologic research.

[106]  T. Hla,et al.  Mapping Pathways Downstream of Sphingosine 1-Phosphate Subtype 1 by Differential Chemical Perturbation and Proteomics* , 2007, Journal of Biological Chemistry.

[107]  K. Wolff,et al.  The fibrin-derived peptide Bβ15–42 protects the myocardium against ischemia-reperfusion injury , 2005, Nature Medicine.

[108]  E. Mackow,et al.  VEGFR2 and Src Kinase Inhibitors Suppress Andes Virus-Induced Endothelial Cell Permeability , 2010, Journal of Virology.

[109]  D. Christiani,et al.  Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans , 2006, PLoS medicine.

[110]  A. Cardona,et al.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. , 2012, The Cochrane database of systematic reviews.

[111]  B. Simon,et al.  Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. , 2004, American journal of respiratory and critical care medicine.

[112]  R. Perng,et al.  Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study , 2011, Critical care.

[113]  M. Bauer,et al.  Angiopoietin-2 Enhances Survival in Experimental Sepsis Induced by Multidrug-Resistant Pseudomonas aeruginosa , 2012, Journal of Pharmacology and Experimental Therapeutics.

[114]  J. Gamble,et al.  Angiopoietin-1 Is an Antipermeability and Anti-Inflammatory Agent In Vitro and Targets Cell Junctions , 2000, Circulation research.

[115]  P. Hu,et al.  Network analysis of transcriptional responses induced by mesenchymal stem cell treatment of experimental sepsis. , 2012, The American journal of pathology.

[116]  M. Molyneux,et al.  The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children , 2010, Critical care.

[117]  J. Garcia,et al.  Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[118]  M. Rojas,et al.  Bone marrow-derived mesenchymal stem cells in repair of the injured lung. , 2005, American journal of respiratory cell and molecular biology.

[119]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.